Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape surrounding Brazilian patent BRPI0507473. The patent, filed by Bristol-Myers Squibb Company, covers compositions containing fixed-dose combinations of specific pharmacological agents. This includes lamivudine, zidovudine, and nevirapine. The patent's validity and enforceability are subject to ongoing examination and potential challenges within the Brazilian patent system.
What is the Subject Matter of BRPI0507473?
The patent BRPI0507473, titled "FIXED DOSE COMBINATIONS CONTAINING LAMIVUDINE, ZIDOVUDINE AND NEVIRAPINE," describes pharmaceutical compositions. The primary subject is a fixed-dose combination of three active pharmaceutical ingredients: lamivudine, zidovudine, and nevirapine. These are antiretroviral drugs commonly used in the treatment of Human Immunodeficiency Virus (HIV) infection.
The invention aims to provide a single pharmaceutical formulation that delivers these three drugs simultaneously. This approach offers several potential advantages, including improved patient compliance due to reduced pill burden and standardized dosing regimens. The patent specifies the synergistic effects and therapeutic benefits derived from administering these compounds in combination.
What Specific Components are Claimed?
Claim 1 of BRPI0507473 describes a pharmaceutical composition comprising:
- Lamivudine
- Zidovudine
- Nevirapine
The claims do not limit the composition to specific ratios or exact dosages but rather to the presence of these three active ingredients. The patent also implies the use of pharmaceutically acceptable carriers, excipients, and diluents, standard for pharmaceutical formulations.
Subsequent claims in the patent may further define:
- Specific ranges of dosages for each active ingredient.
- Dosage forms, such as tablets or capsules.
- Methods of manufacturing these fixed-dose combination products.
- Methods of treating HIV infection using these compositions.
The precise scope of protection is determined by the language of each independent and dependent claim. Analyzing these claims is critical to understanding the patent's breadth and potential for infringement.
What is the Patent Status and Filing History of BRPI0507473?
Patent BRPI0507473 was filed by Bristol-Myers Squibb Company. Understanding its filing history and current status within the Brazilian National Institute of Industrial Property (INPI) is crucial for assessing its commercial implications.
When was BRPI0507473 Filed and Granted?
The filing date for BRPI0507473 is May 26, 2005. The patent was granted on December 27, 2011. The patent term in Brazil is 20 years from the filing date, making its potential expiry in May 2025. However, patent terms can be extended under specific circumstances, particularly for pharmaceutical patents, to compensate for regulatory review delays.
Who is the Assignee of BRPI0507473?
The assignee of patent BRPI0507473 is Bristol-Myers Squibb Company, a global biopharmaceutical company. This indicates that the patent owner has invested in the research and development of this specific drug combination.
Are there any Post-Grant Challenges or Litigation?
As of the current analysis, publicly available information does not indicate any significant post-grant challenges or ongoing litigation specifically targeting patent BRPI0507473 in Brazil. However, the pharmaceutical patent landscape is dynamic. Challenges can arise from generic manufacturers seeking to enter the market, public health organizations, or other patent holders. A thorough legal and market intelligence search would be required to confirm the absence of any dormant or recent challenges.
What is the Patent Landscape for Fixed-Dose Combination Antiretrovirals in Brazil?
The patent landscape for fixed-dose combination (FDC) antiretrovirals in Brazil is complex, influenced by public health policies, patent law, and the presence of both originator and generic drug manufacturers. Patents in this area typically cover:
- New chemical entities with antiviral activity.
- Novel formulations of existing drugs.
- Fixed-dose combinations of approved antiretrovirals.
- Methods of treatment using these combinations.
How Many Patents Cover Similar FDC Antiretroviral Therapies?
The number of patents covering FDC antiretroviral therapies in Brazil is substantial. INPI data and patent databases reveal numerous filings and granted patents related to combinations of antiretrovirals, including but not limited to lamivudine, zidovudine, and nevirapine. These patents are held by various pharmaceutical companies, including global originators and, increasingly, domestic and international generic companies.
Specific FDCs commonly patented include:
- Combinations of nucleoside reverse transcriptase inhibitors (NRTIs) such as lamivudine and zidovudine.
- Combinations of NRTIs with non-nucleoside reverse transcriptase inhibitors (NNRTIs) like nevirapine.
- Combinations involving protease inhibitors (PIs) or integrase strand transfer inhibitors (INSTIs) with other classes of drugs.
For instance, other patents might cover combinations of:
- Tenofovir disoproxil fumarate (TDF), emtricitabine, and efavirenz.
- Abacavir, lamivudine, and dolutegravir.
The competitive landscape is shaped by the expiration dates of these patents, the strength of their claims, and the ability of generic companies to design around existing intellectual property.
What are the Key Patent Holders in this Field?
Key patent holders in the field of FDC antiretrovirals in Brazil include:
- Originator Companies: Major global pharmaceutical companies such as Bristol-Myers Squibb, ViiV Healthcare (a joint venture between GSK, Pfizer, and Shionogi), Gilead Sciences, Merck & Co., and AbbVie have historically held significant patent portfolios.
- Generic Manufacturers: Indian pharmaceutical companies, renowned for their generic drug production, and increasingly, Brazilian pharmaceutical companies, are active in filing and prosecuting patents for generic versions of antiretroviral FDCs or seeking patent protection for their own formulations and manufacturing processes.
The strategy of these entities involves protecting their innovative products while also seeking to secure intellectual property rights over improved formulations or manufacturing techniques that can provide market exclusivity.
How Does Patent Term Extension Affect Market Exclusivity?
In Brazil, Article 40 of Law No. 9,279/96 (Industrial Property Law) provides for a patent term extension of five years for patents that have not yet been granted within a period of ten years from the filing date. This extension is granted to compensate for delays in the examination process by INPI. For pharmaceutical patents, the effective market exclusivity period can therefore extend beyond the standard 20-year term from filing, particularly if the patent was granted late.
This mechanism is crucial for originator companies, as it allows them to recoup R&D investments. For generic companies, patent term extensions can significantly delay their market entry. The application and granting of patent term extensions are subject to specific criteria and can be challenged.
For BRPI0507473, granted in 2011, the standard 20-year term from filing (May 2005) would end in May 2025. Any potential patent term extension beyond this date would depend on the specific circumstances of its examination and approval process at INPI.
What are the Potential R&D and Investment Implications of BRPI0507473?
The existence and scope of patent BRPI0507473 have direct implications for R&D strategies and investment decisions within the pharmaceutical sector.
For Generic Drug Manufacturers
Generic manufacturers must carefully analyze the patent claims of BRPI0507473 and any other relevant patents covering the lamivudine/zidovudine/nevirapine combination.
- Infringement Assessment: Developing a generic version of this FDC requires assessing whether the proposed product infringes any valid and enforceable claims of BRPI0507473. This involves detailed claim construction and analysis.
- "Evergreening" Strategies: Originator companies may have filed subsequent patents covering improved formulations, polymorphs, or manufacturing processes. Generic companies must identify and navigate these "evergreening" patents to ensure freedom to operate.
- Patent Expiry Monitoring: Precise monitoring of the patent expiry date, including any applicable patent term extensions, is essential for market entry planning.
- Paragraph IV Filings (US Equivalent Analogy): While Brazil does not have a direct equivalent to the Hatch-Waxman Act's Paragraph IV certification, generic companies may engage in pre-litigation strategies or post-grant review processes to challenge patent validity.
- Licensing and Collaboration: In some cases, generic companies might seek voluntary licenses from the patent holder, although this is less common for older patents nearing expiry.
For Originator and Innovator Companies
For the patent holder, Bristol-Myers Squibb, BRPI0507473 represents a component of their intellectual property portfolio.
- Market Exclusivity: The patent provides market exclusivity, allowing the company to sell its branded FDC product without direct generic competition for the duration of the patent term.
- Licensing Opportunities: While less likely for an established patent, there could be opportunities for licensing the technology for specific markets or indications, although the primary focus would be on defending market share.
- Portfolio Management: This patent is one of many that protect the company's HIV treatment portfolio. Its expiration will trigger generic competition, necessitating strategic planning for portfolio renewal and the introduction of next-generation therapies.
- R&D Focus: The expiry of patents on older FDCs like the one claimed in BRPI0507473 influences R&D priorities, shifting focus towards newer drug classes, combination therapies with improved efficacy, safety profiles, or simplified dosing regimens.
For Investors
Investors consider patent portfolios as key indicators of a company's competitive advantage and future revenue streams.
- Risk Assessment: The strength, scope, and remaining term of patents like BRPI0507473 inform investment decisions by assessing the risk of patent challenges and the potential for generic competition.
- Market Entry Timing: For companies investing in generic development, understanding patent landscapes helps predict market entry opportunities and potential returns on investment.
- Valuation: The intellectual property assets surrounding a drug, including patents on its FDC, contribute to the valuation of pharmaceutical companies. The impending expiry of BRPI0507473 would factor into the valuation of any product it protects.
Key Takeaways
- Patent BRPI0507473, assigned to Bristol-Myers Squibb Company, covers a fixed-dose combination of lamivudine, zidovudine, and nevirapine.
- The patent was filed on May 26, 2005, and granted on December 27, 2011. Its standard term expires in May 2025, subject to potential patent term extensions.
- The Brazilian patent landscape for FDC antiretrovirals is competitive, with numerous patents held by originator and generic companies.
- Generic manufacturers must conduct thorough freedom-to-operate analyses to assess infringement risks and plan for market entry upon patent expiry.
- Originator companies rely on such patents for market exclusivity and to protect their R&D investments, while investors use patent information to assess risk and market opportunities.
Frequently Asked Questions
What is the primary therapeutic use of the drugs in BRPI0507473?
The primary therapeutic use of lamivudine, zidovudine, and nevirapine is in the treatment of Human Immunodeficiency Virus (HIV) infection.
Can a generic version of the BRPI0507473 combination be launched before its patent expiry?
A generic version can typically only be launched after the relevant patent protection has expired, or if the patent is declared invalid or not infringed by the generic product. This requires careful legal and technical analysis in Brazil.
What is the significance of a "fixed-dose combination" in patent terms?
A fixed-dose combination refers to a single dosage form containing two or more active pharmaceutical ingredients. Patents on FDCs protect the specific combination and its formulation, preventing others from marketing the same combination in a single pill without authorization.
Does INPI automatically grant patent term extensions for pharmaceutical patents?
No, patent term extensions in Brazil are not automatic. They must be applied for and are granted by INPI under specific conditions, primarily to compensate for delays in the examination process.
What legal mechanisms exist in Brazil for challenging pharmaceutical patents like BRPI0507473?
Challenges can include nullity actions (seeking to invalidate a patent based on substantive grounds) and opposition proceedings (which can be filed during the patent prosecution phase). Post-grant reviews and potential litigation are also avenues for challenging patent enforceability.
Citations
[1] Brazilian National Institute of Industrial Property (INPI). (n.d.). Patent Database. Retrieved from [INPI official website - specific URL may vary]
[2] Law No. 9,279, of May 14, 1996. (1996). Industrial Property Law. Presidency of the Republic.
[3] Bristol-Myers Squibb Company. (2011). FIXED DOSE COMBINATIONS CONTAINING LAMIVUDINE, ZIDOVUDINE AND NEVIRAPINE (Patent No. BRPI0507473). Brazilian National Institute of Industrial Property.
